Evaluation of the efficacy of botulinum neurotoxin type A (BoNT-A) in the treatment of erectile dysfunction resistant to phosphodiesterase type 5 inhibitors (PDE5Is): a randomized double-blind clinical trial

Start Date11 Oct 2025

Sponsor / Collaborator-

CTIS2024-513158-32-01

/ RecruitingPhase 4

Exploratory, longitudinal study to define changes in muscle, tendon and neural properties after botuline neurotoxin type A (BoNT) treatment of spastic equinovarus in first-ever stroke patients: a pilot study

Start Date14 Aug 2025

Sponsor / Collaborator

UZ Leuven

NCT06937931

/ RecruitingPhase 2

A Phase II, Multicentre, Randomised, Double-blind, Parallel-Group, Placebo Controlled Study to Evaluate the Efficacy and Safety of IPN10200 as a Treatment for Cervical Dystonia in Adult Participants

The purpose of this study is to evaluate the efficacy and safety of the study drug, IPN10200, and to assess how well it works when compared with placebo in treating Cervical Dystonia (CD) in adults.
CD can cause a series of abnormalities and symptoms in the head and neck that can lead to neck pain and stiffness, and headaches. CD is believed to involve deep parts within the brain that control movement, but genetic factors, environmental factors, and abnormalities in the brain may also play a role.
The usual treatment for CD includes injecting BoNT into the affected muscles, but the treatment only lasts about 3 months. IPN10200 is designed to last for a longer period.
The study will consist of two periods:
1. A Screening Period of up to 4 weeks (28 days) to assess whether a participant can take part in the study and requires at least one visit.
2. A Treatment Period of 36 weeks.
On Day 1 of the treatment period, participants will receive either IPN10200 Dose A or Dose B (additional participants may receive IPN10200 Dose C) of the study drug, or placebo distributed into different muscles in the head, neck and shoulders. Participants may continue some other medications, but details need to be recorded.
There will be 10 visits to the clinic in person and one remote visits (phone call) (12 visits to the clinic for participants who receive Dose C). Participants will undergo blood samplings, urine collections, physical/neurological examinations, and clinical evaluations. Participants will also need to complete questionnaires throughout the study.
The total study duration for a participant will be up to 40 weeks (approximately 9 months).

Start Date30 Jun 2025

Sponsor / Collaborator

Ipsen SA

100 Clinical Results associated with AbobotulinumtoxinA (Ipsen Biopharm Ltd)

100 Translational Medicine associated with AbobotulinumtoxinA (Ipsen Biopharm Ltd)

100 Patents (Medical) associated with AbobotulinumtoxinA (Ipsen Biopharm Ltd)

1,671

Literatures (Medical) associated with AbobotulinumtoxinA (Ipsen Biopharm Ltd)

01 Mar 2026·BIOMATERIALS

DETOX: An innovative dendritic nanosystem for the delivery of BoNT/A LC domain to ischemic neurons

Article

Author: Santos, Sofia D ; Furihata, Tomomi ; Fonseca, Fátima ; Magalhães, Natália ; Leiro, Victoria ; Moreira, Débora A ; Piantino, Marie ; Silva, Duarte ; Torrado, Marília ; Sinthon, Clara ; Matsusaki, Michiya ; Ferreira-da-Silva, Frederico ; Pêgo, Ana P

Ischemic stroke is a leading cause of mortality and morbidity worldwide. Nevertheless, current treatments are very ineffective as they only restore the blood flow, lacking neuroprotective properties. Excitotoxicity, primarily mediated by the overaccumulation of glutamate in the synaptic space, plays a key role in infarct expansion. Therefore, we propose a novel neuroprotective strategy to limit excessive glutamate release using the light-chain (LC) of Botulinum neurotoxin type A (BoNT/A), known to block neurotransmitters exocytosis, transported and delivered with proprietary fully biodegradable PEG-dendritic block copolymers (fbB). Here, the synthesis of 'taggable' dendrimers at their PEG end was further explored, where a Cy5.5 molecule was tagged through this point to allow for the tracking of nanoparticles in complex biological systems. A highly pure and catalytically active LC protein was produced and successfully complexed with the fbB dendrimers, forming DETOX nanoparticles. These systems, with nanosizes and mildly positive net charges, achieved up to 84 % LC-loading efficiency. DETOX significantly enhanced the cleavage of SNAP-25 - the LC's target - in neurons compared to BoNT/A and demonstrated a faster onset of action than the full-length neurotoxin, without inducing cytotoxicity. Importantly, DETOX capacity to reduce glutamate exocytosis was demonstrated in an in vitro model of ischemia. Moreover, DETOX nanoparticles showed their remarkable ability to permeate a 3D full-human blood-brain barrier model, indicating their promising application in humans. These findings position DETOX nanosystems as a groundbreaking neuroprotective strategy, offering a novel, clinically relevant approach for mitigating excitotoxicity in ischemic stroke, paving the way for advanced CNS therapeutics.

01 Mar 2026·TOXICON

Beyond structural divergence: Multiscale computational immunogenicity modelling of botulinum neurotoxin E and cross-reactivity in botulinum neurotoxin A primed hosts

Article

Author: Webb, William Richard ; Rao, Parinitha ; Joseph, John H ; Rahman, Eqram ; Wu, Woffles Tl ; Michon, Alain

Botulinum neurotoxin type E (BoNT/E) is clinically attractive for its rapid onset and short duration of effect but carries uncertain immunogenic risks. Using sequence analysis, structural modelling, and immunoinformatics and multiscale computational workflow platform (AesthetiSIM™), we compared BoNT/E with type A (BoNT/A) across multiple molecular scales. Pairwise alignments revealed modest global identity (34 %) but ≥70 % conservation in immunodominant epitopes within the SNAP-25 cleavage groove and SV2-binding loops, with structural superposition yielding backbone RMSD values of 1.9-2.5 Å. BoNT/E epitopes exhibited greater solvent accessibility (+7-9 % SASA) and more positive electrostatic potentials (+0.42 vs + 0.11 kT/e), favouring HLA class II groove compatibility. Epitope predictions across 27 alleles showed 73 % enrichment of strong binders (IC50 ≤ 50 nM) for BoNT/E, with higher entropy values (0.74-0.83 vs 0.58-0.64), indicating broader repertoire coverage. Docking and molecular dynamics confirmed stronger stability of BoNT/E-HLA complexes (ΔG -44 to -49 kcal/mol, 5-6 hydrogen bonds) compared with BoNT/A (ΔG -30 to -34 kcal/mol, 2-3 bonds). Recall modelling demonstrated that BoNT/A priming amplified BoNT/E binding affinity by 13-16 %, accelerating T-cell activation thresholds. Systems immunology simulations projected neutralizing antibody risk at 9.2 % for BoNT/E versus 7.2 % for BoNT/A at 10 years, with combined A + E regimens reaching 13.7 %. Population coverage analyses predicted BoNT/E epitopes would engage 94 % of individuals globally, increasing to 98 % with A + E. These molecular findings identify BoNT/E as an epitope-dense, highly accessible, and cross-reactive antigen with amplified immunogenicity under simulation, necessitating further exploration with longer clinical trials.

01 Feb 2026·TOXICON

Botulinum neurotoxin A alleviates Deinagkistrodon acutus venom-induced limb injury through promoting macrophage polarization in rabbits

Article

Author: Lan, Pin ; Lai, Linjie ; Wu, Haohao ; Xu, Jiefeng ; Du, Wang ; Xie, Lutao

OBJECTIVE:

Envenomation by Deinagkistrodon acutus (D. acutus) often results in severe limb damage, but therapeutic strategies to counteract the damage are limited. Botulinum neurotoxin A (BoNT/A) has shown protective effects in various models of tissue damage. The present study employed a rabbit model of D. acutus-induced limb damage to investigate the potential therapeutic use and underlying mechanisms of BoNT/A.

METHODS:

Twenty-two New Zealand white rabbits were randomly assigned to three groups: Sham (S, n = 6), Snake Venom (SV, n = 8), and Snake Venom plus BoNT/A (SV + BoNT/A, n = 8). D. acutus venom was injected intramuscularly into the left thigh to cause limb injury. Antivenom (80 U/kg) was given intravenously 2 h later. In the SV + BoNT/A group, BoNT/A was injected subcutaneously around the venom injection site immediately after modeling. The myoglobin, serum creatine kinase, and limb circumference were monitored. After 24 h, muscle tissue near the injection site was collected for histological evaluation, assessment of apoptosis (cleaved caspase-3), analysis of TNF-α, IL-6, and IL-10, and examination of macrophage polarization markers.

RESULTS:

Both SV and SV + BoNT/A groups displayed significant increases in limb swelling, inflammatory cytokines, apoptosis, histological damage, macrophage polarization in comparison to the Sham group. Treatment with BoNT/A reduced pro-inflammatory cytokines (TNF-α, IL-6) while increasing IL-10 (P < 0.05). Moreover, BoNT/A decreased the proportion of CD86⁺ and iNOS + cells (M1 phenotype) while increasing the proportion of CD206+ and Arg1+ cells (M2 phenotype).

CONCLUSION:

BoNT/A alleviates D. acutus -induced limb injury in rabbits potentially through promoting macrophage polarization.

News (Medical) associated with AbobotulinumtoxinA (Ipsen Biopharm Ltd)

21 Jan 2026

·www.galderma.com

Galderma provides update on arbitration case regarding neuromodulator research and development partnership

Zug, Switzerland – January 21, 2026 – Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromodulator research & development partnership with Ipsen. The partnership was limited to the rights and obligations relating to the companies’ early-stage neuromodulator pipeline for aesthetic indications. Galderma welcomes the clarity provided by the arbitral tribunal. This decision has no impact on the commercialization of Galderma’s neuromodulator portfolio. Galderma will continue to commercialize and supply Dysport®/Azzalure®, Alluzience®, and RelfydessTM in all territories where it has regulatory approval and in accordance with our existing agreements with our partner Ipsen. Galderma remains focused on its ambition to become the world’s undisputed dermatology powerhouse across the full spectrum of a fast-growing market, spanning Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Galderma’s business model is flexible – from in-house development to external partnerships. In Injectable Aesthetics specifically, Galderma is on a strong trajectory to become the global leader, not just in sales and market share, but also in innovation. The company is well positioned to lead across the full value chain, with in-house capabilities spanning the discovery, research, development, manufacturing, and marketing of best-in-class products globally. We have proven our capabilities with Restylane® – the broadest HA filler portfolio in the industry; Sculptra® – the first proven regenerative biostimulator; and more recently with RelfydessTM – the first and only ready-to-use liquid neuromodulator created with our proprietary PEARLTM Technology. Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com. For further information: Christian Marcoux, M.Sc. Chief Communications Officer christian.marcoux@galderma.com +41 76 315 26 50 Emil Ivanov Head of Strategy, Investor Relations, and ESG emil.ivanov@galderma.com +41 21 642 78 12 Richard Harbinson Corporate Communications Director richard.harbinson@galderma.com +41 76 210 60 62 Jessica Cohen Investor Relations and Strategy Director jessica.cohen@galderma.com +41 21 642 76 43 Follow us on Social Media for current news and patients stories

14 Jan 2026

·www.biospace.com

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

14 abstracts will be presented across a range of neurological conditions including post‑stroke spasticity, cervical dystonia, blepharospasm and other movement disorders Interim data from the ongoing EPITOME trial 1 showed that 45.7% of stroke survivors with paresis developed post-stroke spasticity within 1 year 18 million treatment years of patient experience. The detailed recommendations for the use of Dysport are described in the Summary of Product Characteristics (SmPC) for Dysport (300 units) Powder and Dysport (500 units) Powder, and the U.S. Prescribing Information (PI). NOTE: Dysport® labels and approved indications may vary from country to country. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries and our partnerships around the world enable us to bring medicines to patients in more than 100 countries. Ipsen is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit Ipsen Contacts Investors Henry Wheeler henry.wheeler@ipsen.com +33 7 66 47 11 49 Khalid Deojee khalid.deojee@ipsen.com +33 6 66 01 95 26 Media Sally Bain sally.bain@ipsen.com +1 857 320 0517 Anne Liontas anne.liontas.ext@ipsen.com +33 7 67 34 72 96 Disclaimers and/or forward-looking statements The forward-looking statements, objectives and targets contained herein are based on Ipsen’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect Ipsen’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words ‘believes’, ‘anticipates’ and ‘expects’ and similar expressions are intended to identify forward-looking statements, including Ipsen’s expectations regarding future events, including regulatory filings and determinations. Moreover, the targets described in this document were prepared without taking into account external-growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by Ipsen. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising medicine in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. Ipsen must face or might face competition from generic medicine that might translate into a loss of market share. Furthermore, the research and development process involves several stages each of which involves the substantial risk that Ipsen may fail to achieve its objectives and be forced to abandon its efforts with regards to a medicine in which it has invested significant sums. Therefore, Ipsen cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the medicine concerned. There can be no guarantees a medicine will receive the necessary regulatory approvals or that the medicine will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation and risks arising from unexpected regulatory or political changes such as changes in tax regulation and regulations on trade and tariffs, such as protectionist measures, especially in the United States; global trends toward healthcare cost containment; technological advances, new medicine and patents attained by competitors; challenges inherent in new-medicine development, including obtaining regulatory approval; Ipsen’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Ipsen’s patents and other protections for innovative medicines; and the exposure to litigation, including patent litigation, and/or regulatory actions. Ipsen also depends on third parties to develop and market some of its medicines which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to Ipsen’s activities and financial results. Ipsen cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of Ipsen’s partners could generate lower revenues than expected. Such situations could have a negative impact on Ipsen’s business, financial position or performance. Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. Ipsen’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers . The risks and uncertainties set out are not exhaustive and the reader is advised to refer to Ipsen’s latest Universal Registration Document, available on ipsen.com . References 1 Zorowitz, R.D., et al. (2026) ‘Sensitivity and specificity of the poststroke spasticity monitoring questionnaire (PSMQ) for remote monitoring of spasticity development: Interim analysis from an ongoing epidemiology study’, Poster presented at TOXINs 2026, Madrid, Spain, [date and time to be confirmed]. 2 Hull M, Anupindi VR, He J, DeKoven M, Goldberg J, Bouchard J. Treatment Patterns and Healthcare Costs Among Patients with Stroke and Spasticity: A 2-Year Longitudinal Study. Neurol Ther. 2025 Feb;14(1):261-278. doi: 10.1007/s40120-024-00692-9. Epub 2024 Dec 17. PMID: 39688805; PMCID: PMC11762044. 3 Zeng et al. Front Neurol . 2021 Jan 20:11:616097. doi: 10.3389/fneur.2020.616097. Attachment Ipsen PR_Toxins 2026_13012026

Phase 1

08 Dec 2025

·www.businesswire.com

Merz Therapeutics to Present Broad Range of Clinical, Real-World and Mechanistic Data at TOXINS 2026

Merz Therapeutics to present more than 20 abstracts and posters at the TOXINS 2026 8 th International Conference, taking place January 14-17 2026 in Madrid, Spain. FRANKFURT, Germany--(BUSINESS WIRE)--Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that the company will present more than 20 clinical and non-clinical abstracts and posters spanning spasticity, movement disorders, and neurotoxin science at the TOXINS 2026 8th International Conference, taking place January 14–17, 2026, in Madrid, Spain. These presentations underscore the company’s commitment to addressing unmet needs in neurological disorders. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “Our research reflects a relentless focus on improving patient outcomes through innovation in neurotoxin science,” said Dr. Stefan Albrecht, Chief Scientific and Medical Officer at Merz Therapeutics. “By presenting these new data at TOXINS 2026, we aim to foster scientific exchange and advance treatment strategies that address real-world challenges for patients and clinicians.” Merz Therapeutics will share new findings reflecting its continued dedication to advancing neurotoxin science. These include: Lower Limb Spasticity IncobotulinumtoxinA for the Treatment of Lower Limb Spasticity in Children and Adolescents with Cerebral Palsy: Evaluation of Lower Limb IncobotulinumtoxinA Efficacy (ELLIE) Authors: Marta Banach, Iryna Makedonska, Veronika Mykhaylenko, Angelika Hanschmann, Thorin Geister, Andrzej Dekundy Presenter: Sebastian Schröder, MD (Germany) Location and Time: Clinical Track 1B – Thursday, 15 January 2026, 17:40 – 17:55 p.m. Upper Limb Spasticity – Shoulder Management Pathways for diagnosis and multimodal management, including botulinum neurotoxin therapy, in shoulder conditions following central lesions Authors: Bo Biering-Sørensen, Carlos Cordero-García, Chris Boulias, Damon Hoad, Djamel Bensmail, Franco Molteni, François Genêt, Jörg Wissel, Philippe Marque, Steffen Berweck, Jorge Jacinto Location and Time: Poster and Exhibit Hall, 14-17 January 2026 Cervical Dystonia Real-world Evidence of Longevity of BoNT/A in Cervical Dystonia (RELY-CD) Authors: Benjamin Wäschle, John Ih Lee, Tristan Kölsche, Robin Jansen, Piotr Sobolewski, Sara Sánchez Valiente, Eva López Valdés, Pablo Mir, Silvia Jesús, Elena Ojeda Lepe, Ewa Papuć, Pilar Sánchez Alonso, Gabriel Salazar, Georg Comes, Holger Stark, Philipp Albrecht Location and Time: Poster and Exhibit Hall, 14-17 January 2026 Pain Evaluating the efficacy and safety of IncobotulinumtoxinA in adults with moderate to severe chronic peripheral neuropathic pain - The Phase 2 PaiNT Study Design Authors: Nadine Attal, Irena Pulte, Ilona Bicker, Ralf Baron, Nanna B. Finnerup, Thorin L. Geister, Eric Viel Location and Time: Poster and Exhibit Hall, 14-17 January 2026 Immunogenicity and Secondary Treatment Failure A systematic review and meta-analysis of neutralizing antibodies after treatment with abobotulinumtoxinA, incobotulinumtoxinA and onabotulinumtoxinA across multiple indications Authors: Uwe Walter, Phillipp Albrecht, Warner Carr, Harald Hefter Location and Time: Poster and Exhibit Hall, 14-17 January 2026 Secondary treatment failure with abobotulinumtoxinA, incobotulinumtoxinA and onabotulinumtoxinA: A systematic review and meta-analysis Authors: Uwe Walter, Phillipp Albrecht, Warner Carr, Harald Hefter Location and Time: Poster and Exhibit Hall, 14-17 January 2026 Toxins congress attendees can connect with Merz Therapeutics at the booth to learn more about the company, its pipeline and ongoing research. About Merz Therapeutics Merz Therapeutics GmbH is dedicated to delivering better outcomes for more patients. With science as its foundation and the patient experience as its focus, the company relentlessly pursues innovative treatments and partnerships to address unmet needs in movement disorders, neurodegenerative conditions, liver disease, and other health conditions that severely impact patients’ quality of life. Merz Therapeutics is headquartered in Frankfurt am Main, Germany, and is active in more than 80 countries. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company with a 117-year legacy. With passion and purpose, Merz Therapeutics continues to advance care in specialty neurology in ways that benefit both patients and society. Please visit www.merztherapeutics.com.

Phase 2

100 Deals associated with AbobotulinumtoxinA (Ipsen Biopharm Ltd)

External Link

KEGG	Wiki	ATC	Drug Bank
D09764	AbobotulinumtoxinA (Ipsen Biopharm Ltd)	M03AX01	DB00083

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Muscle Spasticity	United States	Ipsen Biopharm Ltd.	14 Jun 2017
Limb spasticity	United States	Ipsen Biopharm Ltd.	29 Jul 2016
Glabellar frown lines	United States	Ipsen Biopharm Ltd.	29 Apr 2009
Torticollis	United States	Ipsen Biopharm Ltd.	29 Apr 2009
Dystonia	Austria	Ipsen SA	28 Jan 2009
Dystonia	Belgium	Ipsen SA	28 Jan 2009
Dystonia	Bulgaria	Ipsen SA	28 Jan 2009
Dystonia	Croatia	Ipsen SA	28 Jan 2009
Dystonia	Cyprus	Ipsen SA	28 Jan 2009
Dystonia	Czechia	Ipsen SA	28 Jan 2009
Dystonia	Denmark	Ipsen SA	28 Jan 2009
Dystonia	Estonia	Ipsen SA	28 Jan 2009
Dystonia	Finland	Ipsen SA	28 Jan 2009
Dystonia	France	Ipsen SA	28 Jan 2009
Dystonia	Germany	Ipsen SA	28 Jan 2009
Dystonia	Greece	Ipsen SA	28 Jan 2009
Dystonia	Hungary	Ipsen SA	28 Jan 2009
Dystonia	Iceland	Ipsen SA	28 Jan 2009
Dystonia	Ireland	Ipsen SA	28 Jan 2009
Dystonia	Italy	Ipsen SA	28 Jan 2009

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Migraine Disorders	Phase 3	Italy	Ipsen SA	12 Oct 2023
Migraine Disorders	Phase 3	United Kingdom	Ipsen SA	12 Oct 2023
Migraine With Aura	Phase 3	United States	Ipsen SA	29 Sep 2023
Migraine With Aura	Phase 3	Canada	Ipsen SA	29 Sep 2023
Migraine With Aura	Phase 3	Czechia	Ipsen SA	29 Sep 2023
Migraine With Aura	Phase 3	France	Ipsen SA	29 Sep 2023
Migraine With Aura	Phase 3	Germany	Ipsen SA	29 Sep 2023
Migraine With Aura	Phase 3	Poland	Ipsen SA	29 Sep 2023
Migraine With Aura	Phase 3	Spain	Ipsen SA	29 Sep 2023
Migraine Without Aura	Phase 3	United States	Ipsen SA	29 Sep 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05167864 (JBDX, CTgov)	Not Applicable	-	143	Onabotulinumtoxina for Injection (OnabotulinumtoxinA)	uhntfrqrgq(kbmiuyufzc) = fhalhtzsiw zrpnlapqsp (vxkcdrjnlf, 5.0) View more	-	17 Jan 2025
				Abobotulinumtoxina for Injection (AbobotulinumtoxinA)	uhntfrqrgq(kbmiuyufzc) = ihshhpzibp zrpnlapqsp (vxkcdrjnlf, 5.2) View more
NCT05277337 (STAR \| Phase IV study, CTgov)	Phase 4	Glabellar frown lines	150	Alluzience (Group 1 (Alluzience))	tqbmauirmx(dbgwtjgdur) = ptrxkglnvf svqsayriuy (qekozbjxwy, 0.414) View more	-	16 Feb 2024
				BoNT-A+Vistabel (Group 2 (Powder BoNT-A: BOTOX/Vistabel))	tqbmauirmx(dbgwtjgdur) = jkvzkcffhd svqsayriuy (qekozbjxwy, 0.831) View more
NCT03543254 (CTgov)	Phase 2	Migraine Disorders \| Chronic Disease	20	BoNT-A	pimrggwetw = ybotyyqkwg ucdznmmwut (ymndiptqyq, xhwqdepgkt - vbnmxwelmf) View more	-	30 Jan 2024
NCT03469999 (CTgov)	Phase 3	Cerebral Palsy	12	Dysport	nucfphhrip(apmeqvnxao) = fqbydfmesl cqludopwny (gbvvxgafvy, jmwcpixkdv - kaupjnkjta) View more	-	01 Jun 2022
NCT01459666 (CTgov)	Phase 4	Cicatrix \| Forehead lines \| Skin Neoplasms ... View more	9	Dysport (Dysport (abobotulinumtoxinA))	kvuvvszbjv(ykzimzvwpp) = kidniemlvw vbcsgvuulh (tkgdkiiycv, chzsgzsmig - jsjjopfamn) View more	-	26 May 2022
				Bacteriostatic 0.9% Sodium Chloride (vehicle) (Placebo)	kvuvvszbjv(ykzimzvwpp) = idslyhudmd vbcsgvuulh (tkgdkiiycv, emzdzgpxgz - wnkikofkyc) View more
NCT02660138 (CONTENT1, CTgov)	Phase 3	Urinary Incontinence \| Neurogenic detrusor overactivity \| Spinal Cord Injuries ... View more	227	placebo (Placebo)	midplqzlhs(dhirdanuiq) = yxvweqlgcr xkyngoxevs (kildqdqlrh, 2.01) View more	-	16 Jun 2021
				Dysport (Dysport® 600 U)	midplqzlhs(dhirdanuiq) = tfjwrokdvn xkyngoxevs (kildqdqlrh, 2.04) View more
NCT03736928 (CTgov)	Phase 2	Glabellar frown lines	401	placebo	kwdnhknxst = oqccukggec pndjsmdbxy (jsdkmpbyvk, yhizndinrc - hebzemnjxb) View more	-	11 Feb 2021
NCT04080882 (CTgov)	Phase 2	-	80	Placebo (Placebo)	vdtbsobbio = podrrgauup fhkfjywedl (liurjcxtre, dkuluppwmw - xsaepebclg) View more	-	22 Jan 2021
				AbobotulinumtoxinA dose 1 (AbobotulinumtoxinA Dose 1)	vdtbsobbio = jjxfmukdis fhkfjywedl (liurjcxtre, lhnjrdnkbf - kjylhoziqa) View more
AAN2020	Not Applicable	Dystonia	43	OnabotulinumToxinA	mpunlpjejx(sasfotcsyc) = vbvlsehxfh wljcuhvzlu (ytnqymhojf ) View more	-	14 Apr 2020
AAN2020	Not Applicable	Muscle Spasticity First line	210	Oral antispastic medications	knnjkppflp(kehopbtgqf) = cqaufhybno zpmzqxjojh (gmaahhhwmu )	-	14 Apr 2020
				Home physiotherapy	xgwwbksapi(jqsymnhvrg) = rikxsgoeiu xmdmbuoidd (mnphbhdhlu )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis